Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UCLG805
- Development stage
- Preclinical
- Lead developer
- UTC Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
UCLG805 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by UTC Therapeutics. It is engineered to target glypican-3 (GPC3), a cell-surface oncofetal antigen highly expressed in hepatocellular carcinoma (HCC). The therapy is produced using a lentiviral vector (LVV) and incorporates UTC Therapeutics' proprietary LACO-Stim® technology, which is designed to enhance T-cell stimulation and improve the persistence and efficacy of CAR-T cells against solid tumors. UCLG805 is currently being evaluated in preclinical studies for the treatment of GPC3-positive hepatocellular cancer.
02
Targets
Beyond the preview
Go deeper on UCLG805.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCLG805.